pharmadog
fetch the data · sniff the signal
© 2026 pharmadog.xyz
made by humans and a good dog
🐶
ZEPBOUND · pharmadog
pharmadog › drugs › ZEPBOUND patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice. Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
ZEPBOUND Marketed updated 2mo ago / tur-ZEP-ə-tyde /
by $LLY ELI LILLY & Co 🔗 ChEMBL Approved annual revenue · 2024–2024 peak $4.9B
2024: $4.9B 2024 $4.9B
community read 0 votes
↑ 0 good boy ↓ 0 doghouse
Protein drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.
targets Glucagon-like peptide 1 receptor Gastric inhibitory polypeptide receptor
News(0) no news has mentioned this drug yet
trade names
Mounjaro, Mounjaro (autoinjector), Zepbound, Zepbound (autoinjector)
MOA
12.1 Mechanism of Action Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. GLP-1 is a physiological regulator of appetite and caloric intake. Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. Both GIP receptors and GLP-1 receptors are found in areas of the brain involved in appetite regulation. Animal studies show that tirzepatide distributes to and activates neurons in brain regions involved in regulation of appetite and food intake.
indication
type 2 diabetes
Data sources
last refreshed 2m ago
Found something off? report 🐶 something off?
Report a data issue Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.
cancel send
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
Patent cliff source: FDA Orange Book first barrier falls
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (216) Dec 30, 2041 method-of-use (U-4193) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4193) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4193) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4193) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4192) US 12295987 Dec 30, 2041 method-of-use (U-4193) US 12295987 Dec 30, 2041 method-of-use (U-4193) US 12295987 Dec 30, 2041 method-of-use (U-4193) US 12295987 Jul 22, 2039 method-of-use (U-4409) US 12343382 Jul 22, 2039 method-of-use (U-4232) US 12343382 Jul 22, 2039 method-of-use (U-4232) US 12343382 Jul 22, 2039 method-of-use (U-4232) US 12343382 Jul 22, 2039 method-of-use (U-4232) US 12343382 Jul 22, 2039 method-of-use (U-4228) US 12343382 Jul 22, 2039 method-of-use (U-4227) US 12343382 Jul 22, 2039 method-of-use (U-4231) US 12343382 Jul 22, 2039 method-of-use (U-4230) US 12343382 Jul 22, 2039 method-of-use (U-4230) US 12343382 Jul 22, 2039 method-of-use (U-4230) US 12343382 Jul 22, 2039 method-of-use (U-4230) US 12343382 Jul 22, 2039 method-of-use (U-4230) US 12343382 Jul 22, 2039 method-of-use (U-4229) US 12343382 Jul 22, 2039 method-of-use (U-4230) US 12343382 Jul 22, 2039 method-of-use (U-4230) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4409) US 12343382 Jul 22, 2039 method-of-use (U-4409) US 12343382 Jul 22, 2039 method-of-use (U-4409) US 12343382 Jul 22, 2039 method-of-use (U-4409) US 12343382 Jul 22, 2039 method-of-use (U-4409) US 12343382 Jul 22, 2039 method-of-use (U-4400) US 12343382 Jul 22, 2039 method-of-use (U-4401) US 12343382 Jul 22, 2039 method-of-use (U-4400) US 12343382 Jul 22, 2039 method-of-use (U-4400) US 12343382 Jul 22, 2039 method-of-use (U-4409) US 12343382 Jul 22, 2039 method-of-use (U-4409) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4409) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4409) US 12343382 Jul 22, 2039 method-of-use (U-4410) US 12343382 Jul 22, 2039 method-of-use (U-4400) US 12343382 Jul 22, 2039 method-of-use (U-4400) US 12343382 Jul 22, 2039 method-of-use (U-4232) US 12343382 Jul 22, 2039 method-of-use (U-4230) US 12343382 Jul 22, 2039 method-of-use (U-4400) US 12343382 Jul 22, 2039 method-of-use (U-4400) US 12343382 Jul 22, 2039 method-of-use (U-4230) US 12343382 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4309) US 12453758 Jul 22, 2039 method-of-use (U-4311) US 12453758 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4309) US 12453758 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4311) US 12453758 Jul 22, 2039 method-of-use (U-4311) US 12453758 Jul 22, 2039 method-of-use (U-4311) US 12453758 Jul 22, 2039 method-of-use (U-4311) US 12453758 Jul 22, 2039 method-of-use (U-4311) US 12453758 Jul 22, 2039 method-of-use (U-4311) US 12453758 Jul 22, 2039 method-of-use (U-4311) US 12453758 Jul 22, 2039 method-of-use (U-4311) US 12453758 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4308) US 12453758 Jul 22, 2039 method-of-use (U-4311) US 12453758 Jun 14, 2039 composition US 11357820 Jun 14, 2039 composition US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 composition US 11357820 Jun 14, 2039 composition US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 composition US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 composition US 11357820 Jun 14, 2039 formulation US 11357820 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-3855) US 11918623 Jun 14, 2039 method-of-use (U-4377) US 12453755 Jun 14, 2039 method-of-use (U-4385) US 12453755 Jun 14, 2039 method-of-use (U-4386) US 12453755 Jun 14, 2039 method-of-use (U-4378) US 12453755 Jun 14, 2039 method-of-use (U-4386) US 12453755 Jun 14, 2039 method-of-use (U-4381) US 12453755 Jun 14, 2039 method-of-use (U-4380) US 12453755 Jun 14, 2039 method-of-use (U-4377) US 12453755 Jun 14, 2039 method-of-use (U-4378) US 12453755 Jun 14, 2039 method-of-use (U-4386) US 12453755 Jun 14, 2039 method-of-use (U-4376) US 12453755 Jun 14, 2039 method-of-use (U-4383) US 12453755 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jun 14, 2039 formulation US 12453756 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 Jan 5, 2036 composition US 9474780 FDA exclusivities (62) Dec 19, 2028 NPP New Product (3y) 2.5y Dec 19, 2028 NPP New Product (3y) 2.5y Dec 19, 2028 NPP New Product (3y) 2.5y Dec 19, 2028 NPP New Product (3y) 2.5y Dec 19, 2028 NPP New Product (3y) 2.5y Dec 19, 2028 NPP New Product (3y) 2.5y $LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
Dec 19, 2028
NPP
New Product (3y)
2.5y
Dec 19, 2028 NPP New Product (3y) 2.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Dec 20, 2027 I-958 Indication (3y) 1.5y
Oct 18, 2027 M-82 Method (3y) 1.3y
Oct 18, 2027 M-82 Method (3y) 1.3y
Oct 18, 2027 M-82 Method (3y) 1.3y
Oct 18, 2027 M-82 Method (3y) 1.3y
Oct 18, 2027 M-82 Method (3y) 1.3y
Oct 18, 2027 M-82 Method (3y) 1.3y
Oct 18, 2027 M-82 Method (3y) 1.3y
Oct 18, 2027 M-82 Method (3y) 1.3y
Oct 18, 2027 M-82 Method (3y) 1.3y
Oct 18, 2027 M-82 Method (3y) 1.3y
Oct 18, 2027 M-82 Method (3y) 1.3y
Oct 18, 2027 M-82 Method (3y) 1.3y
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
May 13, 2027 NCE New Chemical Entity (5y) 310d
Nov 8, 2026 NP NP 124d
Nov 8, 2026 NP NP 124d
Nov 8, 2026 NP NP 124d
Nov 8, 2026 NP NP 124d
Nov 8, 2026 NP NP 124d
Nov 8, 2026 NP NP 124d $LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
🐶 often sniffed alongside top 6 
comments(0)
5-min edit window · permanent after that